NCT03548467 - A Study to Evaluate Safety and Efficacy of Multiple Dosing With VB10.NEO and Bempegaldesleukin (NKTR-214) Immunotherapy in Patients With Locally Advanced or Metastatic Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 4, 2018

Primary Completion Date

January 30, 2023

Study Completion Date

January 30, 2023

Conditions

Locally Advanced or Metastatic Solid Tumours

Interventions

BIOLOGICAL

VB10.NEO

VB10.NEO is a vaccine and is supplied as a sterile, ready to use solution (14 vaccinations will be given).

DRUG

Bempegaldesleukin

0.006 mg/kg bempegaldesleukin (NKTR-214) will be administered intravenously q4w for up to 11 doses starting from week 11 or at any dosing visit up to week 34 and for up to week 50 (up to 11 doses). The first 2 doses will be in a Q3W interval and following doses in Q4W intervals.

Trial Locations (6)

60488

Krankenhaus Nordwest gGmbH, Frankfurt

68167

Universitätsmedizin Mannheim, Mannheim

69120

University Hospital Heidelberg, NCT, Im Neuenheimer Feld 460, Heidelberg

81675

Klinik und Poliklinik für Innere Medizin III, Hämatologie und Onkologie, Munich

Unknown

Charité Research Organisation, Campus Benjamin Franklin, Berlin

Martin-Luther-Universität Halle-Wittenberg, Universitätsklinikum Halle (Saale), Halle